Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559320 | 0.87 | RAB9A (0.50) | RAB9ANPC1KMT2AFFAR2SMN1; SMN2 | |
| SCHEMBL31220873 | 0.80 | RAB9A (0.61) | RAB9ANPC1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29806164 | 0.80 | RAD52 (0.53) | RAB9ANPC1KMT2AALDH1A1KDM4E | |
| SCHEMBL3550056 | 0.79 | RAB9A (0.53) | RAB9ANPC1KMT2AFFAR2SMN1; SMN2 | |
| SCHEMBL14758463 | 0.79 | RAB9A (1.00) | RAB9ANPC1KMT2AFFAR2SMN1; SMN2 | |
| SCHEMBL22971333 | 0.77 | KDR (0.44) | RAB9ANPC1KMT2AALDH1A1KDM4E | |
| SCHEMBL2793375 | 0.77 | NPC1 (0.54) | RAB9ANPC1NFKB1KMT2ASMN1; SMN2 | |
| SCHEMBL15145230 | 0.77 | AURKA (0.56) | RAB9ANPC1KMT2AKDM4EPOLB | |
| SCHEMBL28324147 | 0.77 | KMT2A (0.61) | RAB9ANPC1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31343853 | 0.76 | RAB9A (0.59) | RAB9ANPC1NFKB1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709315-A | The inhibitor of bruton's tyrosine kinase | 药品循环有限责任公司 | 2018-02-16 | — | — | CN | disclosed |
| US-9115112-B2 | Aminoanthracene derivative and an organic electroluminescent element employing the same | DOOSAN CORPORATION (KR) | 2015-08-25 | — | — | US | disclosed |
| US-9115112-B2 | Aminoanthracene derivative and an organic electroluminescent element employing the same | DOOSAN CORPORATION (KR) | 2015-08-25 | — | — | US | disclosed |
| US-9115112-B2 | Aminoanthracene derivative and an organic electroluminescent element employing the same | DOOSAN CORPORATION (KR) | 2015-08-25 | — | — | US | disclosed |
| US-20120161615-A1 | AMINOANTHRACENE DERIVATIVE AND AN ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | DOOSAN CORPORATION (KR) | 2012-06-28 | — | — | US | disclosed |
| US-20120161615-A1 | AMINOANTHRACENE DERIVATIVE AND AN ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | DOOSAN CORPORATION (KR) | 2012-06-28 | — | — | US | disclosed |
| US-20120161615-A1 | AMINOANTHRACENE DERIVATIVE AND AN ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | DOOSAN CORPORATION (KR) | 2012-06-28 | — | — | US | disclosed |
| WO-2010147318-A2 | AMINOANTHRACENE DERIVATIVE AND AN ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | 주식회사 두산 (KR) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120161615-A1 | AMINOANTHRACENE DERIVATIVE AND AN ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | AADAT, ALAD, AAAS | RAB9A 2311/4885NPC1 4829/4885NFKB1 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.